No synergistic effect of subtherapeutic doses of donepezil and EVP‐6124 in healthy elderly subjects in a scopolamine challenge model

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 5 - Trang 89-98 - 2019
Anne Catrien Baakman, Ricardo Alvarez-Jimenez1, Gordon Loewen2, Marieke L. de Kam1, Karen Broekhuizen1, Dana C. Hilt2, Geert Jan Groeneveld1
1Centre for Human Drug Research, Leiden, the Netherlands
2Forum Pharmaceuticals, Waltham, USA

Tóm tắt

AbstractIntroductionDonepezil is a widely used cholinesterase inhibitor in the management of Alzheimer's disease. Despite large‐scaled evidence for its efficacy, elevated peripheral ACh levels often lead to side effects and are dose limiting. The present exploratory study is designed to determine the potentiation of the effects of donepezil by cotreatment with EVP‐6124, an alpha‐7 nicotinic agonist, to reduce scopolamine‐induced cognitive deficits in healthy elderly subjects. Secondary objectives are to explore safety and pharmacokinetic and pharmacodynamics effects of EVP‐6124 alone and in combination with donepezil compared to placebo.MethodsA phase I randomized, single‐center, placebo‐controlled, double‐blind, five‐way, partial crossover study was performed with donepezil 2.5, 5 mg or placebo combined with EVP‐6124 0.3, 1, 2, 4 mg or placebo in three cohorts of healthy elderly subjects in a scopolamine (0.3 mg i.v.) challenge test. Safety, pharmacokinetic, and pharmacodynamics outcomes were assessed.ResultsA total of 36 subjects completed the study. Donepezil pharmacokinetic parameters were similar with and without EVP‐6124. Effective dose combinations were donepezil/EVP‐6124(5/2 mg) and donepezil/EVP‐6124 (5/0.3 mg) and showed improvements of the delayed recall of the Visual Verbal Learning Test (1.2; CI = 0.1–2.3) and reaction time during the two‐back condition of the N‐back (−42; CI = −77, −8), respectively. Overall, no marked reversal of scopolamine effects was observed.DiscussionThis study shows no synergistic effect of subtherapeutic doses of donepezil and EVP‐6124 in a scopolamine challenge model in healthy elderly subjects. Dosing of scopolamine and the combination of donepezil and EVP‐6124 requires further study.

Tài liệu tham khảo

2012, Dementia: a public health priority 10.1016/j.jalz.2007.04.381 J.Birks.Cholinesterase inhibitors for Alzheimer's disease.Cochrane Database Syst Rev 2006;Cd005593 10.1016/S1474-4422(03)00502-7 10.1176/appi.ajp.162.4.676 Weed M.R., 2017, Nicotinic alpha 7 receptor agonists EVP‐6124 and BMS‐933043, attenuate scopolamine‐induced deficits in visuo‐spatial paired associates learning, PLoS one, 12, e0187609, 10.1371/journal.pone.0187609 10.1586/14737175.2015.995639 10.1016/j.neuropharm.2011.10.024 Clinicaltrials.gov.Safety Tolerability and Pharmacokinetic Study of EVP‐6124 in Patients With Alzheimer's Disease.https://clinicaltrialsgov/ct2/show/NCT00766363 Clinicaltrials.gov.Safety and Cognitive Function Study of EVP‐6124 in Patients With Mild to Moderate Alzheimer's Disease.https://clinicaltrialsgov/ct2/show/NCT01073228 Clinicaltrials.gov.Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP‐6124 in Subjects With Alzheimer's Disease.https://clinicaltrialsgov/ct2/show/NCT01969123 Clinicaltrials.gov.Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP‐6124 in Subjects With Alzheimer's Disease.https://clinicaltrialsgov/ct2/show/NCT01969136 Effects Sideline Some Phase 3 Encenicline Trials.https://www.alzforum.org/news/research‐news/rare‐severe‐side‐effects‐sideline‐some‐phase‐3‐encenicline‐trials. Rare but Severe Side 2015 10.1111/j.1365-2125.2011.03936.x 10.1016/j.jalz.2005.09.004 10.1016/j.clinthera.2014.09.013 10.1002/j.1552-4604.1998.tb04812.x 10.1016/j.neuropsychologia.2008.04.010 10.1097/01.ftd.0000168293.48226.57 10.1016/j.ddtec.2016.07.004 10.1080/01688639408402654 10.1159/000147471 10.1177/026988119701100405 10.1001/archneur.1994.00540240033012 10.1136/jnnp.73.6.665 10.1002/hbm.20163 10.1037/0096-1523.31.3.438 10.1111/j.1365-2125.1984.tb02583.x 10.1111/j.1365-2125.1975.tb00465.x 10.1097/00004714-199808000-00007 10.1007/BF02244655 10.1038/clpt.1991.122 10.1177/026988119901300102 10.1177/0269881106071550 10.1002/1097-4679(197707)33:3<786::AID-JCLP2270330340>3.0.CO;2-X 10.1046/j.1365-2125.2002.t01-10-01714.x 10.1016/0028-3908(71)90039-6 10.1212/WNL.25.11.1065 10.1111/j.1365-2125.1983.tb01495.x Wright B.M., 1971, A simple mechanical ataxia‐meter, J Physiol, 218, 27p 10.1177/0269881108092595 10.1177/0269881109106942 10.1177/0269881109105573 10.1097/00004647-199702000-00012 Siegfried K.R., 1993, Pharmacodynamic and early clinical studies with velnacrine, Acta Neurol Scand Supplementum, 149, 26 10.1007/BF02244648 10.1111/j.1749-6632.1991.tb00226.x 10.1007/s00213-011-2344-y 10.1111/bcp.13031
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 5

89-98

Thông tin tác giả